(poe TASS ee um EYE oh dide)
- Saturated Potassium Iodide Solution
- Saturated Solution of Potassium Iodide
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
SSKI: 1 g/mL (30 mL, 237 mL)
ThyroShield: 65 mg/mL (30 mL [DSC]) [contains brilliant blue fcf (fd&c blue #1), fd&c red #40, methylparaben, propylene glycol, propylparaben, saccharin sodium; black raspberry flavor]
iOSAT: 130 mg [scored]
ThyroSafe: 65 mg [scored]
Brand Names: U.S.
- iOSAT [OTC]
- ThyroSafe [OTC]
- ThyroShield [OTC] [DSC]
- Antithyroid Agent
Reduces viscosity of mucus by increasing respiratory tract secretions; inhibits secretion of thyroid hormone, fosters colloid accumulation in thyroid follicles. Following radioactive iodine exposure, potassium iodide blocks the uptake of radioactive iodine by the thyroid, reducing the risk of thyroid cancer.
Onset of Action
Hyperthyroidism: 24 to 48 hours (Nayak 2006); Peak effect: ~2 weeks after continuous therapy (Nayak 2006)
Duration of Action
Radioactive iodine exposure: Each dose has a duration of ~24 hours
Use: Labeled Indications
Antidote: Block thyroidal uptake of radioactive isotopes of iodine in a nuclear radiation emergency.
Expectorant: Expectorant for the symptomatic treatment of chronic pulmonary diseases complicated by mucous.
Off Label Uses
Graves hyperthyroidism (following radioactive iodine therapy)
Data from a retrospective study suggest that potassium iodide may be beneficial in select patients with Graves hyperthyroidism (eg, those who would be candidates for but are allergic to antithyroid drugs) in order to shorten the duration of hyperthyroidism after receiving radioactive iodine therapy [Ross 1983]. Additional data may be necessary to further define the role of potassium iodide in this condition.
Sporotrichosis (cutaneous, lymphocutaneous)
Based on the Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 update, potassium iodide is recommended as alternative therapy for nonpregnant adults and children with cutaneous or lymphocutaneous sporotrichosis who do not respond to or otherwise cannot receive itraconazole.
Based on the American Thyroid Association and American Association of Clinical Endocrinologists guidelines for the management of hyperthyroidism and other causes of thyrotoxicosis, potassium iodide is recommended in the immediate preoperative period in patients with Graves disease undergoing thyroidectomy to reduce thyroid blood flow, vascularity, and intraoperative blood loss. Potassium iodide is not recommended in the preoperative setting in patients with thyrotoxicosis caused by a toxic adenoma or toxic multinodular goiter due to the risk of exacerbating hyperthyroidism [Ross 2016].
Thyroid gland protection during radiopharmaceutical use
Based on the European Association of Nuclear Medicine (EANM) procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy and the guidelines for radioiodinated MIBG scintigraphy in children, potassium iodide is effective and recommended when given as thyroid gland protection during radiopharmaceutical use.
Thyrotoxic crisis/thyroid storm
Clinical experience suggests the utility of potassium iodide in managing children with thyrotoxic crisis/thyroid storm [Eyal 2008]. Additional data may be necessary to further define the role of potassium iodide for the treatment of this condition.
Based on the American Thyroid Association and American Association of Clinical Endocrinologists guidelines for the diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis, potassium iodide given to adults for thyrotoxic crisis/thyroid storm is effective and recommended in the management of this condition.
Hypersensitivity to iodide, iodine, or any component of the formulation; dermatitis herpetiformis; hypocomplementemic vasculitis, nodular thyroid condition with heart disease
Expectorant (SSKI): Oral: 300 to 600 mg (0.3 to 0.6 mL) 3 to 4 times daily
Antidote [thyroid block following nuclear radiation emergency (iOSAT, ThyroSafe, ThyroShield)]: Includes pregnant/lactating women: Oral: 130 mg once daily, continue for 10 to 14 days or as directed by public officials (until risk of exposure has passed or other measures are implemented)
Thyroidectomy preparation (off-label use): Oral: 50 to 100 mg (1 to 2 drops or 0.05 to 0.1 mL SSKI) 3 times daily; administer for 10 days before surgery; if not euthyroid prior to surgery, consider concurrent beta-blockade (eg, propranolol) in the immediate preoperative period to reduce the risk of thyroid storm (Ross 2016)
Sporotrichosis (cutaneous, lymphocutaneous; off-label use) (SSKI): Oral: Initial: 5 drops 3 times daily; increase to 40 to 50 drops 3 times daily as tolerated until 2 to 4 weeks after lesions have resolved (usual duration 3 to 6 months) (Kauffman 2007)
Thyroid gland protection during radiopharmaceutical use (off-label use): Oral: Tablet: 130 mg once daily or Solution (SSKI): 4 drops 3 times daily (Bexxar prescribing information 2012). Note: Begin at 1 to 48 hours prior to exposure. Continue potassium iodide after radiopharmaceutical administration until risk of exposure has diminished (treatment duration and time of initiation is dependent on the radiopharmaceutical, consult specific protocol).
Thyrotoxic crisis/thyroid storm (off-label use): Oral: Note: Administer at least 1 hour after antithyroid drug administration (eg, propylthiouracil, methimazole): SSKI 250 mg (5 drops or 0.25 mL) every 6 hours (Ross 2016)
Refer to adult dosing.
Antidote [thyroid block following nuclear radiation emergency (iOSAT, ThyroSafe, ThyroShield)]: Infants, Children, and Adolescents: Dosing should continue for 10 to 14 days or as directed by public officials (until risk of exposure has passed or other measures are implemented): Oral:
Infants ≤1 month: 16.25 mg once daily
Infants >1 month to Children ≤3 years: 32.5 mg once daily
Children >3 to ≤12 years: 65 mg once daily
Children >12 years and Adolescents weighing <68 kg: 65 mg once daily
Children >12 years and Adolescents weighing ≥68 kg: 130 mg once daily
Sporotrichosis (cutaneous, lymphocutaneous) (off-label use) (SSKI): Children and Adolescents: Oral: Initial: 50 mg (1 drop or 0.05 mL) 3 times daily; increase as tolerated up to a maximum of 2,500 mg (50 drops or 2.5 mL) or 1 drop/kg (0.05 mL/kg) 3 times daily, whichever is lower; continue for 2 to 4 weeks after lesions have resolved (usual duration: 3 to 6 months) (Kauffman 2007)
Thyroidectomy preparation (off-label use) (SSKI): Children and Adolescents: Oral:
Patients unable to receive concurrent antithyroid therapy: 150 to 350 mg (3 to 7 drops or 0.15 to 0.35 mL) 3 times daily (Ross 2016)
Patients receiving concurrent antithyroid therapy: 50 to 100 mg (1 to 2 drops or 0.05 to 1 mL) 3 times daily (Ross 2016)
Note: Administer SSKI for 10 days before surgery. If patient is not euthyroid prior to surgery, consider concurrent beta-blockade (eg, propranolol) in the immediate preoperative period to reduce the risk of thyroid storm.
Thyroid gland protection during radiopharmaceutical use (off-label use): Infants, Children, and Adolescents: Oral:
Infants <5 kg: 16 mg once daily (Giammarile 2008)
Infants and Children 1 month to 3 years or 5 to 15 kg: 32 mg once daily (Giammarile 2008; Olivier 2003)
Children and Adolescents 3 to 13 years or 15 to <50 kg: 65 mg once daily (Giammarile 2008; Olivier 2003)
Adolescents >13 years or ≥50 kg: 130 mg once daily (Giammarile 2008; Olivier 2003)
Note: Begin at 1 to 48 hours prior to exposure. Continue potassium iodide after radiopharmaceutical administration until risk of exposure has diminished (treatment duration and time of initiation is dependent on the radiopharmaceutical, consult specific protocol.
Thyrotoxic crisis/thyroid storm (off-label use): Oral: Note: Administer preferably 2 hours after antithyroid drug administration:
Infants: SSKI 100 mg (2 drops or 0.1 mL) 4 times daily (Eyal 2008)
Children: SSKI 250 mg (5 drops or 0.25 mL) 2 to 4 times daily (Eyal 2008)
Dosing: Renal Impairment
There are no dosage adjustments provided in the manufacturer's labeling; use with caution.
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer's labeling.
A 16.25 mg/5 mL oral solution may be made with tablets. Crush one 130 mg tablet and reduce to a fine powder. Add 20 mL of water and mix until powder is dissolved. Add an additional 20 mL of low-fat milk (white or chocolate), orange juice, flat soda, raspberry syrup, or infant formula. Stable for 7 days under refrigeration. Discard any unused portion.
To prepare an 8.125 mg/5 mL oral solution, crush one 65 mg tablet and reduce to a fine powder. Add 20 mL of water and mix until powder is dissolved. Add an additional 20 mL of low-fat milk (white or chocolate), orange juice, flat soda, raspberry syrup, or infant formula. Stable for 7 days under refrigeration. Discard any unused portion.
SSKI: Dilute in a glassful of water, fruit juice, or milk. Administer with food or milk to decrease gastric irritation.
iOSAT, Thyrosafe, Thyroshield: Administer as soon as possible after instructed to do so by public officials. Do not take more than 1 dose in 24 hours. Tablets may be administered whole or crushed and then mixed with water, low fat milk (white or chocolate), orange juice, soda (flat), raspberry syrup, or infant formula. Raspberry syrup disguises the taste best; low-fat white milk or water do not hide the salty taste well) (AAP 2003). See Extemporaneously Prepared.
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Keep tightly closed.
SSKI: If exposed to cold, crystallization may occur. Warm and shake to redissolve. If solution becomes brown/yellow, it should be discarded.
iOSAT, Thyrosafe: Keep dry and intact in foil.
ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors. Monitor therapy
Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. Monitor therapy
Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Monitor therapy
Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides. Monitor therapy
Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Consider therapy modification
Heparin: May enhance the hyperkalemic effect of Potassium Salts. Monitor therapy
Heparin (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts. Monitor therapy
Lithium: Potassium Iodide may enhance the hypothyroid effect of Lithium. Monitor therapy
Nicorandil: May enhance the hyperkalemic effect of Potassium Salts. Monitor therapy
Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Consider therapy modification
Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131. Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration. Avoid combination
Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives. Exceptions: Dyphylline. Monitor therapy
Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists. Consider therapy modification
Iodide may alter thyroid function tests.
Frequency not defined.
Cardiovascular: Cardiac arrhythmia
Central nervous system: Confusion, fatigue, fever, numbness, tingling sensation
Dermatologic: Skin rash, urticaria
Endocrine & metabolic: Goiter, hyperthyroidism (prolonged use), hypothyroidism (prolonged use), myxedema
Gastrointestinal: Diarrhea, enlargement of salivary glands, gastric distress, gastrointestinal hemorrhage, metallic taste, nausea, stomach pain, vomiting
Hematologic & oncologic: Lymphedema, thyroid adenoma
Hypersensitivity: Hypersensitivity reaction (angioedema, cutaneous and mucosal hemorrhage, serum sickness-like symptoms)
Neuromuscular & skeletal: Weakness
Respiratory: Dyspnea, wheezing
Miscellaneous: Iodine poisoning (with prolonged treatment/high doses)
Concerns related to adverse effects:
• Hypersensitivity: Iodide hypersensitivity may occur, manifesting as angioedema, cutaneous/mucosal hemorrhage, and serum sickness-like symptoms (fever, arthralgia, lymph node enlargement, and eosinophilia).
• Skin reactions: Can cause acne flare-ups and/or dermatitis.
• Thyroid adverse effects: Prolonged use may lead to hypothyroidism. Iodide may cause underactive or overactive thyroid; thyroid enlargement may also occur. Use with caution in patients with a history of hyperthyroidism; use is contraindicated in patients with nodular thyroid condition (goiter) with heart disease. Iodism or chronic iodide poisoning may occur with high doses or prolonged treatment; symptoms include burning of mouth/throat, sore teeth/gums, severe headache, metallic taste, eye irritation/eye lid swelling, increased salivation, acneform skin lesions, and (rarely) severe skin lesions; withhold potassium iodide treatment and manage with supportive care.
• Adrenal insufficiency: Use with caution in patients with Addison disease.
• Bronchitis: Use with caution in patients with acute bronchitis.
• Cardiac disease: Use with caution in patients with cardiac disease.
• Myotonia congenita: Use with caution in patients with myotonia congenita.
• Renal impairment: Use with caution in patients with renal impairment
• Tuberculosis: Use with caution in patients with tuberculosis.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Pediatric: In a nuclear radiation emergency, infants and children are more likely to experience thyroid damage. Neonates <1 month are at higher risk for hypothyroidism with potassium iodide use; evaluate thyroid function if repeat dosing is required in this patient population.
• Appropriate use: For thyroid gland protection (radiopharmaceutical use), potassium iodide must be administered prior to receiving radiopharmaceuticals that require thyroid gland protection. For nuclear radiation emergency, take only when instructed by public health officials; do not take more or more often than instructed; follow other emergency measures recommended by officials.
Thyroid function tests (thyroid function should be monitored in pregnant or breast-feeding women, neonates, and young infants if repeat doses are required following radioactive iodine exposure); signs/symptoms of hypo- or hyperthyroidism
Pregnancy Risk Factor
Iodide crosses the placenta (may cause hypothyroidism and goiter in fetus/newborn). Use as an expectorant during pregnancy is contraindicated by the AAP (AAP 1976). Use for protection against thyroid cancer secondary to radioactive iodine exposure is considered acceptable based upon risk:benefit, keeping in mind the dose and duration (AAP 2003). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003). Pregnant women should take as instructed by public officials and contact their physician. Repeat dosing should be avoided if possible (AAP 2003). Refer to Iodine monograph for additional information.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience nausea, vomiting, abdominal pain, or diarrhea. Have patient report immediately to prescriber dysphagia, difficulty speaking, wheezing, cough, shortness of breath, arrhythmia, angina, joint pain, swelling of neck, swelling of arms or legs, black, tarry, or bloody stools, vomiting blood, burning or numbness feeling, severe loss of strength and energy, confusion, severe headache, metallic taste, teeth or gingival changes, burning of mouth or throat, eye irritation, eyelid edema, drooling, or skin irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
More about potassium iodide
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- 1 Review – Add your own review/rating
- Drug class: antithyroid agents